Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 5/20 | 0.54 |
| ▸ | S1PR5 | Q9H228 | 9/20 | 0.52 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.46 |
| ▸ | SCN4A | P35499 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL798026 | 0.92 | MEN1 (0.56) | S1PR1S1PR5S1PR4MEN1KMT2A | |
| SCHEMBL15942972 | 0.89 | S1PR5 (0.63) | S1PR1S1PR5S1PR4MEN1KMT2A | |
| SCHEMBL797980 | 0.88 | S1PR1 (0.60) | S1PR1S1PR5S1PR4MEN1KMT2A | |
| SCHEMBL5791973 | 0.83 | MEN1 (0.60) | S1PR1S1PR5S1PR4MEN1KMT2A | |
| SCHEMBL12174984 | 0.82 | SCN4A (0.62) | S1PR1S1PR5S1PR4MEN1KMT2A | |
| SCHEMBL5567542 | 0.82 | SCN4A (0.62) | S1PR1S1PR5S1PR4MEN1KMT2A | |
| SCHEMBL12174911 | 0.82 | SCN4A (0.62) | S1PR1S1PR5S1PR4MEN1KMT2A | |
| SCHEMBL797358 | 0.81 | SIGMAR1 (0.57) | SIGMAR1 | |
| SCHEMBL13242411 | 0.80 | S1PR5 (0.74) | S1PR1S1PR5S1PR4S1PR3 | |
| SCHEMBL12891076 | 0.80 | ALDH1A1 (0.53) | S1PR1MEN1KMT2ASIGMAR1TEAD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802663-B2 | Pyrazole oxadiazole derivatives as S1P1 agonists | MERCK SERONO SA (CH) | 2014-08-12 | — | — | US | disclosed |
| US-20120071460-A1 | PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS | MERCK SERONO SA (CH) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071460-A1 | PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR5 4/4885S1PR4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.